These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 32478071)

  • 1. Pros and Cons of Denosumab Treatment for Osteoporosis and Implication for RANKL Aptamer Therapy.
    Zhang N; Zhang ZK; Yu Y; Zhuo Z; Zhang G; Zhang BT
    Front Cell Dev Biol; 2020; 8():325. PubMed ID: 32478071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.
    Dempster DW; Lambing CL; Kostenuik PJ; Grauer A
    Clin Ther; 2012 Mar; 34(3):521-36. PubMed ID: 22440513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The role of rank-ligand inhibition in the treatment of postmenopausal osteoporosis].
    Varenna M; Gatti D
    Reumatismo; 2010; 62(3):163-71. PubMed ID: 21052563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review of denosumab for the treatment of osteoporosis.
    Miyazaki T; Tokimura F; Tanaka S
    Patient Prefer Adherence; 2014; 8():463-71. PubMed ID: 24748775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can denosumab be a substitute, competitor, or complement to bisphosphonates?
    Kim SY; Ok HG; Birkenmaier C; Kim KH
    Korean J Pain; 2017 Apr; 30(2):86-92. PubMed ID: 28416991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of RANK/RANKL signal transduction pathway: a promising approach for osteoporosis treatment.
    Bai YD; Yang FS; Xuan K; Bai YX; Wu BL
    Med Hypotheses; 2008 Aug; 71(2):256-8. PubMed ID: 18445511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Updates of denosumab, anti-RANKL antibody for osteoporosis].
    Tokuyama N; Tanaka S
    Clin Calcium; 2014 Jan; 24(1):85-91. PubMed ID: 24369284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The mechanism of anti-RANKL antibody in the treatment of metabolic bone diseases including osteoporosis - possible applications of anti-RANKL antibody to the treatment of cancer patients].
    Yasuda H
    Nihon Yakurigaku Zasshi; 2019; 153(1):11-15. PubMed ID: 30643086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Denosumab for the treatment of osteoporosis.
    Iqbal J; Sun L; Zaidi M
    Curr Osteoporos Rep; 2010 Dec; 8(4):163-7. PubMed ID: 20857349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RANK ligand inhibition with denosumab for the management of osteoporosis.
    Lewiecki EM
    Expert Opin Biol Ther; 2006 Oct; 6(10):1041-50. PubMed ID: 16989586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-RANKL antibody was approved for the treatment of osteoporosis in Japan.
    Yasuda H
    Nihon Rinsho Meneki Gakkai Kaishi; 2013; 36(4):209-16. PubMed ID: 23994799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New and emerging concepts in the use of denosumab for the treatment of osteoporosis.
    Lewiecki EM
    Ther Adv Musculoskelet Dis; 2018 Nov; 10(11):209-223. PubMed ID: 30386439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Skeletal and extraskeletal actions of denosumab.
    Sinningen K; Tsourdi E; Rauner M; Rachner TD; Hamann C; Hofbauer LC
    Endocrine; 2012 Aug; 42(1):52-62. PubMed ID: 22581255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Denosumab: anti-RANKL antibody.
    Miller PD
    Curr Osteoporos Rep; 2009 Mar; 7(1):18-22. PubMed ID: 19239825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RANKL, a necessary chance for clinical application to osteoporosis and cancer-related bone diseases.
    Yasuda H
    World J Orthop; 2013 Oct; 4(4):207-17. PubMed ID: 24147256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Denosumab. The first inhibitor of RANK-ligand for treatment of osteoporosis].
    Bruhn C
    Med Monatsschr Pharm; 2010 Oct; 33(10):370-5. PubMed ID: 21072910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Therapeutic agents for disorders of bone and calcium metabolism--Denosumab, a fully human monoclocal antibody-targeting RANKL as a therapy for cancer-induced bone diseases].
    Mera K; Ito K
    Clin Calcium; 2007 Jan; 17(1):37-46. PubMed ID: 17211092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Denosumab: an investigational drug for the management of postmenopausal osteoporosis.
    Lewiecki EM
    Biologics; 2008 Dec; 2(4):645-53. PubMed ID: 19707445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RANKL as a target for the treatment of osteoporosis.
    Matsumoto T; Endo I
    J Bone Miner Metab; 2021 Jan; 39(1):91-105. PubMed ID: 33057808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biologic Antiresorptive: Denosumab.
    Kumar L; Arora MK; Marwah S
    Indian J Orthop; 2023 Dec; 57(Suppl 1):127-134. PubMed ID: 38107799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.